Yıl: 2005 Cilt: 20 Sayı: 2 Sayfa Aralığı: 59 - 65 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Huzursuz bacak sendromunda güncel tedavi

Öz:
HBS (Huzursuz Bacak Sendromu): Hastalarda, bacaklarını hareket ettirme dürtüsüyle ortaya çıkan, duyusal ve motor semptomlarla seyreden, kronik, ilerleyici veya tekrarlayıcı ve yaşla beraber prevalansı artan bir sensorimotor hastalıktır. HBS'nin tedavisinde başlıca, demir eksikliği, periferik nöropati, diabet ve üremi gibi sekonder nedenlerin tedavisi gerektirmektedir. İdioapatik başlangıçlı primer veya sekonder HBS tedavisinde L-DOPA (L-Dihidroksi fenil alanin) ilk seçilecek ilaçtır. L-DOPA tedavisi sırasında %50 hastada tedavi sürerken HBS semptomlarının kötüleşmesi gelişebilir. Dopamin agonistlerinden pergolide, pramipexole, ropinirole ve cabergoline HBS'nin tedavisinde kullanılan dopaminerjik ilaçlardır. Opioidler, benzodiazepinler ve gabapentin gibi antikonvulzan ilaçlar dopamin agonistlerine cevap vermeyen veya ilacı tolere edemeyen olgularda düşünülmelidir. HBS güncel tedavisinde, uzun süreli kullanımda etkili, güvenilir, yan etki profili düşük ilaç seçiminin gereği vurgulanmıştır.
Anahtar Kelime: Dopamin agonistleri Huzursuz bacak sendromu

Konular: Romatoloji

Current theraphy of the restless legs syndrome

Öz:
RLS (Restless legs syndrome) is a sensorimotor disorder characterized by an urge or need to move the limbs usually associated with sensory and motor symptoms, chronic progressive or relapsing remitting course and prevalance increase with age. The treatment of RLS include the treatment of secondary causes such as iron deficiency anemia, periferic neuropathy, diabetes, uremia. L-DOPA (L-Dihydroxyphenylalanine) is the first line drugs for treatment of both primary and secondary RLS patients. % 50 percent of patients may develop augmentation (worsening of RLS symptomps in the course of therapy) by L-DOPA therapy. Dopamine agonists such as pergolide, pramipexole, ropinirole, cabergoline are dopaminergic agents used in the treatment of RLS. Opioids, benzodiazepines and anticonvulsants such as gabapentin can be considered when dopamine agonists not respond or not tolerable by patients. The current therapy of RLS include drugs which are effective on longterm usage and yet have minimal adverse events and safety.
Anahtar Kelime: Restless Legs Syndrome Dopamine Agonists

Konular: Romatoloji
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Allen RP, Early CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 2001;18:128-147.
  • 2. Earley CJ, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000;54:1698-1700.
  • 3. Trenkwalder C, Paulus W. Why do restless legs occur at rest?-pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2). Clin Neurophysiol 2004;115:1975-1988.
  • 4. American Sleep Disorders Association. The international classification of sleep disorders, revised: diagnostic and coding manual. Rochester, Minn.: American Sleep Disorders Association, 1997:65-68.
  • 5. Phillips B, Youn T, et al. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000;160(14):2137- 2141.
  • 6. Rothdach AJ, Trenkwalder C, Haberstock J, et al. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and morbidity in augsburg elderly. Neurology 2000;54:1064-1068.
  • 7. Ulfberg J. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001;16(6):1159-1163.
  • 8. Berger K. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004;164(2):196- 202.
  • 9. Hening W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004;5:237-24.
  • 10. Walters AS. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995;10(5):634-642.
  • 11. Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology 1996;47(6):1435-1441.
  • 12. O'Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing 1994;23(3):200-203.
  • 13. Stiasny K, Wetter TC, Trenkwalder C, et al. Restless legs syndrome and its treatment by dopamine agonists. Park Rel Dis 2001;7:21-25.
  • 14. Saletu M, Anderer P, Hogl B et al. Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr- L-dopa in restless legs syndrome. J Neural Transm 2003;110(6):611-626.
  • 15. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/Levodopa. Sleep 1996;19:205-213.
  • 16. Ondo W, Romanyshyn J, Vuong, et al. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 2004;61(9):1393-1397.
  • 17. Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional SR-L-dopa in L-dopa responsive RLS with late night symptoms. Neurology 1999;52:285-290.
  • 18. Walters AS, Hening WA, Kavey N, et al. A double-blind randomized cross-over trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol 1988;24(3):455-458
  • 19. Wetter TC, Stiasny K, Winkelmann J, et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999;52:944-950.
  • 20. Trenkwalder C, Brandenburg U, Hundemer HP, and the PEARLS Study Group. A randomized long-term placebocontrolled multicenter trial of pergolide in the treatment of restlesss legs syndrome with central evaluation of polysomnographic data. Neurology 2001;56(Suppl. 3):A5
  • 21. Winkelmann J, Wetter TC, Stiasny K, et al. Treatment of restless legs syndrome with pergolide-an open clinical trial. Mov Disord 1998;13:566-569.
  • 22. Trenkwalder C, Hundemer HP, Lledo A, et al. PEARLS Study Group; Pergolide European Australian RLS. Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study. Neurology 2004;62(8):1391-7.
  • 23. Stiasny K, Roebbecke J, Schüler P, Oertel WH. Treatment of idiopathic restless legs syndrome (RLS) with the D2- agonist cabergoline- an open clinical trial. Sleep 2000;23(3):349-354
  • 24. Stiasny K, Roebbecke J, Schüler P, et al. Treatment of restless legs syndrome (RLS) with cabergoline. J Neurol 1998;245:405.
  • 25. Zucconi M, Oldani A, Castronovo C, et al. Cabergoline is an effective single-drug treatment for restless legs syndrome: clinical and actigraphic evaluation. Sleep 2003;26(7):815-818.
  • 26. Benes H, Heinrich CR, Ueberall MA, et al. Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an openlabel 6-month clinical trial. Sleep 2004;27(4):674-82.
  • 27. Ondo W. Ropinirole for restless legs syndrome. Mov Disord 1999;14(1):138-140.
  • 28. Estivill E, de la Fuente V. The efficacy of ropinirole in the tratment of chronic insomnia secondary to restless legs syndrome: polysomnography data. Rev Neurol 1999;29(9):805-807.
  • 29. Saletu M, Anderer P, Saletu B, Hauer C, et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology 2000;41(4):190-199.
  • 30. Adler CH, Hauser RA, Sethi K, et al. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology 2004;62(8):1405-1407.
  • 31. Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004;27(5):907-914.
  • 32. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Therapy with Ropinirole; Efficacy and Tolerability in RLS 1 Study Group. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomized, placebo-controlled study in 10 European countries. J Neurol Neurosurg Psychiatry2004;75(1):92-97
  • 33. Walters AS, Ondo WG, Dreykluft T, et al. Ropinirole is effective in the treatment of restless legs syndrome . TREAT RLS 2: A 12 week, double-blind, randomized, paralel-group, placebo-controlled study. Mov Disord 2004;19(12):1414-1423.
  • 34. Montplaisir J, Nicolas A, Denesle R, et al. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999;52(5):938-943.
  • 35. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. European J of Neurol 2000;7(Suppl. 1):27-31.
  • 36. Stiasny K, Moeller JC, Oertel WH. Safety of pramipexole in patients with restless legs syndrome. Neurology 2000;55(2):1589-1590.
  • 37. Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004;5(1):9-14.
  • 38. Ferini-Strambi L. Restless legs syndrome augmentation and pramipexole treatment. Sleep Med 2002;3:S23-25.
  • 39. Stiasny K, Oertel WH. Low-dose pramipexole in the management of restless legs syndrome. An open label trial. Neuropsychobiology 2004;50(1):65-70.
  • 40. Stiasny K, Kohnen R, Schollmayer E, et al. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: A double-blind, placebo-controlled pilot study. Mov Disord. 2004;19(12):1432-1438.
  • 41. Benes H, Deibler A, Clarenbach P, et al. Lisuridin the management of restless legs syndrome-an extended polysomnographic study. Mov Disord 2000;15(Suppl.3):134.
  • 42. Sonka K, Pretl M, Kranda K. Management of restless legs syndrome by the partial D2 agonistterguride. Sleep Med 2003;4:455-457.
  • 43. Evidente VGH, Adler CH, Caviness JN, et al. Amantadine is beneficial in restless legs syndrome. Mov Disord 2000;15(2):324-327.
  • 44. Reuter I, Ellis CM, Chauduri KR. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 1999;100(3):163-167
  • 45. Priano L, Albani G, Brioschi A, et al. Restless legs syndrome augmentation and pramipexole treatment. Neurol Sci 2003;24(3):207-208.
  • 46. Walters AS, Wagner ML, Hening WA, et al. Succesful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993;16(4):327-3332.
  • 47. Allen RP, Kaplan PW, Buchholz DW, et al. Double-blinded, placebo controlled comparison of high dose propoxyphene and moderate dose carbidopa/Levodopa for treatment of periodic limb movements in sleep. Sleep Res 1992;21:166.
  • 48. Lauerma H, Markkula J Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry 1999;60(4):241-244.
  • 49. Telstad W, Sorensen O, Larsen S, et al. Treatment of the restless legs syndrome with carbamazepine: a doubleblind study. Br Med J (Clin Res Ed):1984;288(6415):444-446.
  • 50. Zucconi M, Coccagna G, Petronelli R, et al. Nocturnal myoclonus in restless legs syndrome effects of carbamazepine treatment. Funct Neurol 1989;4(3):263-271.
  • 51. Ehrenberg BL, Eisensehr I, Corbett KE, et al. Valproate for sleep consolidation in periodic limb movement disorder. J Clin Psychopharmacol 2000;20:574-578.
  • 52. Happe S, Klösch G, Saletu B et al. Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology 2001;57:1717-1719.
  • 53. Borreguero DG, Larrosa O, Llave Y, et al. Treatment of restless legs syndrome with gabapentin. Neurology 2002;59:1573-1579.
  • 54. Adler CH. Treatment of restless legs sydrome with gabapentin. Clin Neuropharmacol 1997;20(2):148-151.
  • 55. Thorp ML, Morris CD, Bagby SP, et al. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001;38:104-108.
  • 56. Taylor CP. An update on the possible mechanisms of action of gabapentin. Dolor 1999;14:237-242.
  • 57. Pugsley TA, Whetzel SZ, Dooley DJ. Reduction of 3,4- diaminopyridine-induced biogenic amine synthesis and release in rat brain by gabapentin. Psychopharmacology 1998;137:74-80.
  • 58. Micozkadýoðlu H, Özdemir FN, Kut A, et al. Gabapentin versus Levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study. Ren Fail 2004; 26(4):393-397.
  • 59. Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Medicine 1996;100:333-337.
  • 60. Guilleminault C, Flagg W. Effect of baclofen on sleeprelated periodic leg movements. Ann Neurol 1984;15:234-239.
  • 61. Wagner ML, Walters AS, Coleman RG, et al. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 1996;19(1):52-58.
  • 62. Nofzinger EA, Fasiczka A, Berman S, et al. Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. J Clin Psychiatry 2000;61:858-862.
  • 63. Perez AV. Topiramate use as treatment in restless legs syndrome. Actas Esp Psiquiatr. 2004;32(3):132-7.
APA ACAR S, GENCER A (2005). Huzursuz bacak sendromunda güncel tedavi. , 59 - 65.
Chicago ACAR Suat,GENCER Ahmet Murat Huzursuz bacak sendromunda güncel tedavi. (2005): 59 - 65.
MLA ACAR Suat,GENCER Ahmet Murat Huzursuz bacak sendromunda güncel tedavi. , 2005, ss.59 - 65.
AMA ACAR S,GENCER A Huzursuz bacak sendromunda güncel tedavi. . 2005; 59 - 65.
Vancouver ACAR S,GENCER A Huzursuz bacak sendromunda güncel tedavi. . 2005; 59 - 65.
IEEE ACAR S,GENCER A "Huzursuz bacak sendromunda güncel tedavi." , ss.59 - 65, 2005.
ISNAD ACAR, Suat - GENCER, Ahmet Murat. "Huzursuz bacak sendromunda güncel tedavi". (2005), 59-65.
APA ACAR S, GENCER A (2005). Huzursuz bacak sendromunda güncel tedavi. Romatizma Dergisi , 20(2), 59 - 65.
Chicago ACAR Suat,GENCER Ahmet Murat Huzursuz bacak sendromunda güncel tedavi. Romatizma Dergisi 20, no.2 (2005): 59 - 65.
MLA ACAR Suat,GENCER Ahmet Murat Huzursuz bacak sendromunda güncel tedavi. Romatizma Dergisi , vol.20, no.2, 2005, ss.59 - 65.
AMA ACAR S,GENCER A Huzursuz bacak sendromunda güncel tedavi. Romatizma Dergisi . 2005; 20(2): 59 - 65.
Vancouver ACAR S,GENCER A Huzursuz bacak sendromunda güncel tedavi. Romatizma Dergisi . 2005; 20(2): 59 - 65.
IEEE ACAR S,GENCER A "Huzursuz bacak sendromunda güncel tedavi." Romatizma Dergisi , 20, ss.59 - 65, 2005.
ISNAD ACAR, Suat - GENCER, Ahmet Murat. "Huzursuz bacak sendromunda güncel tedavi". Romatizma Dergisi 20/2 (2005), 59-65.